Home » Stocks » PVCT

Provectus Biopharmaceuticals, Inc. (PVCT)

Stock Price: $0.0615 USD 0.0000 (0.00%)
Updated December 2, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 24.66M
Revenue (ttm) n/a
Net Income (ttm) -6.56M
Shares Out 393.50M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 2
Last Price $0.0615
Previous Close $0.0615
Change ($) 0.0000
Change (%) 0.00%
Day's Open -
Day's Range 0.0600 - 0.0000
Day's Volume 0
52-Week Range 0.0000 - 0.0000

More Stats

Market Cap 24.66M
Enterprise Value 47.15M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 393.50M
Float n/a
EPS (basic) -0.01
EPS (diluted) -0.02
FCF / Share -0.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.82M
Short Ratio 0.47
Short % of Float n/a
Beta 0.85
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.44
Revenue n/a
Operating Income -4.98M
Net Income -6.56M
Free Cash Flow -4.27M
Net Cash -22.49M
Net Cash / Share -0.06
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -210.69%
ROE n/a
ROIC -84.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$3.50*
Low
3.50
Current: $0.0615
High
3.50
Target: 3.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-6.30-8.05-13.32-24.95-24.65-16.81-13.03-14.34-21.44-20.69
Net Income-6.92-8.15-13.52-24.43-24.50-10.24-27.70-12.57-19.43-18.55
Shares Outstanding38738236923419617613211310678.82
Earnings Per Share-0.02-0.02-0.04-0.12-0.13-0.06-0.22-0.11-0.19-0.37
Operating Cash Flow-6.19-5.20-10.35-21.94-17.41-13.85-9.89-11.26-17.20-13.73
Capital Expenditures---0.03--0.01-0.07-0.01-0.02-0.01-
Free Cash Flow-6.19-5.20-10.38-21.94-17.42-13.92-9.90-11.27-17.21-13.73
Cash & Equivalents0.590.050.111.1714.1817.3915.701.227.718.09
Total Debt20.3713.939.46-------
Net Cash / Debt-19.78-13.88-9.351.1714.1817.3915.701.227.718.09
Assets1.481.993.445.6120.4426.1820.016.2013.3514.40
Liabilities25.5519.4113.462.144.120.9913.381.813.333.70
Book Value-24.07-17.42-10.023.4716.3225.196.634.3910.0210.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Provectus Biopharmaceuticals, Inc.
Country United States
Employees 2

Stock Information

Ticker Symbol PVCT
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: PVCT

Description

Provectus Biopharmaceuticals, a clinical-stage biotechnology company, engages in developing drugs based on halogenated xanthenes for oncology, hematology, and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase Ib/II study for metastatic melanoma; Phase I study for hepatocellular carcinoma and other solid tumors metastatic to the liver; and non-clinical assessment of pediatric cancer tumor cell. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.